This Article  • References  • Full text PDF  • Correction  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Roger E. Meyer, MD

Arch Gen Psychiatry. 1992;49(11):900-904.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Over the past decade, a number of factors have served to focus national attention on the prospects for developing effective pharmacologic treatment to reduce cocaine dependence. The media, the general public, and its elected leaders became alarmed about the spread of cocaine use, abuse, and dependence.¹ Traditional drug treatment programs reported that cocaine dependence was less amenable to established treatment strategies,^2,3 while researchers cited animal data on the powerful reinforcing potency of the drug.⁴ The historical success of methadone maintenance treatment for heroin addiction, combined with a growing base of research on the neuropharmacology of cocaine, suggested that some new pharmacotherapy offered the best and most cost-effective hope for a seemingly intractable and growing problem. Knowledge of some of the residual effects of cocaine and/or stimulants in the central nervous system^5-7 and of kindling phenomena related to repeated cocaine administration⁸ led to a number of . . . [Full Text PDF of this Article]

Author Affiliations
From the Department of Psychiatry, University of Connecticut School of Medicine, Farmington.

Footnotes
Accepted for publication June 18, 1992.

Reprint requests to 10 Talcott Notch Rd, Farmington, CT 06032 (Dr Meyer).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?